RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Healthcare
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment...
New England Life Care Selects Inovalon’s ScriptMed® to Scale Infusion Therapy and Specialty Pharmacy
ScriptMed Infusion will Accelerate New England Life Care's Patient-Centric Care and Scale Pharmacy OperationsBOWIE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE)...
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of...
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics,...
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered...
Teleflex awarded Short Term Central Venous Catheters contract from Vizient
Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a...
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in...
Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE)...
KFSHRC’s Study Named Among Top 10 Most Impactful Papers of 2024
RIYADH, Saudia Arabia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its...
Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region
Jie Xue Özlem Fidanci January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US...
MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia
EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorderHELSINKI, Jan. 09, 2025 (GLOBE NEWSWIRE)...
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added...
Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 08, 2025 (GLOBE NEWSWIRE)...
Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE)...
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on...